Bellicum announces interim bpx-601 data and corporate restructuring

Houston, oct. 29, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its bpx-601 dose-escalation clinical trial in patients with relapsed/refractory metastatic pancreatic cancer. findings from the first four patients treated with bpx-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated car-t cell activation. clinically meaningful efficacy as measured by recist criteria was not observed.
BLCM Ratings Summary
BLCM Quant Ranking